Homology Medicines Inc

For the period ended Dec 31, 2023. Filed Mar 13, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 13, 2024

QTTB$9.25+4.5%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
2023 · 2022
Assets
Current assets:
Cash and cash equivalents	$39,266		$33,986
Short-term investments	43,387		141,040
Assets held for sale	260		—
Prepaid expenses and other current assets	1,001		5,989
Total current assets	83,914		181,015
Equity method investment	—		25,814
Property and equipment, net	—		1,078
Right-of-use assets	650		20,563
Total assets	$84,564		$228,470
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$3,234		$1,144
Accrued expenses and other liabilities	7,021		18,715
Operating lease liabilities	1,318		1,561
Deferred revenue	—		1,156
Total current liabilities	11,573		22,576
Non-current liabilities:
Operating lease liabilities, net of current portion	—		27,916
Total liabilities	11,573		50,492
Commitments and contingencies (Note 10)		—
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022	—		—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 58,017,412 and 57,483,910 shares issued and outstanding as of December 31, 2023 and 2022, respectively	6		6
Additional paid-in capital	615,088		607,513
Accumulated other comprehensive loss	(5)		(404)
Accumulated deficit	(542,098)		(429,137)
Total stockholders’ equity	72,991		177,978
Total liabilities and stockholders' equity	$84,564		$228,470

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.